Rapid technology advancements have given narrow gauge surgery the edge in diabetic cases
Vitrectomy has been proven as an effective treatment for patients with proliferative diabetic retinopathy (PDR) and many surgeons are now using narrow gauge instrumentation to perform the surgery. However, previous literature has revealed some potential disadvantages to the technique and it has been questioned whether narrow gauge surgery is associated with an increased rate of peripheral retinal break formation in macular surgery and also of relevance, a lower success rate in retinal reattachment surgery than 20G surgery.1,2
Achieving the surgical aims
To examine the incidence of retinal break formation in patients being treated for PDR, Dr Steel and colleagues retrospectively reviewed a group of 170 eyes. Half of the eyes comprised the control group and underwent conventional 20G surgery and the other half were treated with 23G transconjunctival vitrectomy surgery.
"We analysed a variety of factors in the case mix to see if the groups could be compared in a meaningful way including basic demographics, for example, it is known younger patients have a higher incidence of retinal break formation during diabetic vitrectomy, as well as a variety of metabolic indicators (e.g., HbAic)," added Dr Steel. "We also looked at the surgery performed - hence analysed the proportion of combined cases and in particular and importantly the extent and position of vitreoretinal adhesion, which defines the complexity of the cases."
Dr Steel reported that while he was transitioning from using 20G to 23G surgery he continued to perform the former technique on complex cases. Therefore, he excluded patients that were operated on during that period from the study.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Evaluating the clinical performance of ZEISS AT ELANA and the new ’ELISA’* approach
July 30th 2025In this insightful analysis, Dr. Joong Hun Kim presents real-world clinical outcomes with bilateral implantation of ZEISS AT ELANA 841P. Dr. Kim recommends AT ELANA® 841P as an excellent option for patients undergoing cataract surgery as its fully trifocal optical design translates into a full range of vision. He also introduces the so-called ‘ELISA’ approach for patients requiring astigmatic correction in one eye only, combining AT ELANA 841P and ZEISS AT LISA tri toric 939MP. Early objective and subjective clinical data from this novel approach reveal promising visual outcomes and high patient satisfaction